A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE STUDY TO COMPARE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF PF-04965842 IN ADULT SUBJECTS WITH MILD AND MODERATE HEPATIC IMPAIRMENT RELATIVE TO SUBJECTS WITH NORMAL HEPATIC FUNCTION
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Abrocitinib (Primary)
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 08 Feb 2019 Planned End Date changed from 1 Apr 2019 to 1 May 2019.
- 08 Feb 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Apr 2019.
- 19 Dec 2018 Planned End Date changed from 1 Mar 2019 to 1 Apr 2019.